In the following video, Motley Fool health-care analyst David Williamson takes a look at Eli Lilly's (NYSE: LLY ) strong 3.6% dividend yield. David tells us that while 3.6% is a slightly higher yield than some of Eli's American peers, there may be several potential looming threats to the company's dividend. David highlights those threats for investors and tells us how concerned we should be.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more, click here to claim your copy today.